Sumitomo Chemical Company, Limited
【Sumitomo Chemical】Financial Results for FY2026 | Sales of ¥2.33 trillion, Net Income of ¥6.09 billion | Released on May 14, 2026
Sumitomo Chemical posted sales of ¥2.3285 trillion and net income of ¥6.094 billion for FY2026. Segments such as agrochemicals and pharmaceuticals performed well, with favorable contributions from Sumitomo Pharma's North American expansion. Outlook for 2027 remains steady.
Key Figures
- Sales: ¥2,328,515 million (YoY △10.7%)
- Net income attributable to owners of parent: ¥60,947 million (YoY +170.3%)
- Total assets: ¥3,405,041 million (decreased)
AI要約
Performance Overview
Sumitomo Chemical achieved sales of ¥2.3285 trillion and net income of ¥6.094 billion for FY2026. The agrochemical and pharmaceutical segments performed steadily, notably with contributions from Sumitomo Pharma's North American operations. Operating income was ¥1,517 billion, a decrease compared to the previous term, but net income saw a significant increase. The company plans to continue steady business development and new investments, with a positive outlook for 2027.
Impact on Shareholders and Future Outlook
Dividends are planned at ¥7.5 per share for the fiscal year-end, resulting in an annual dividend of ¥13.5 per share, an increase from previous levels. The 2027 earnings guidance projects sales of ¥2.36 trillion and net income of ¥700 million, with attention to risks such as currency fluctuations and raw material prices. The company intends to actively promote R&D and capital investments, planning to raise approximately ¥111.6 billion through new share issuance and stock offerings, focusing on research in oncology and neurodegenerative diseases.
Sumitomo Chemical Co., Ltd.
Company overview · Stock price · Financial data · All IR
